For research use only. Not for therapeutic Use.
Nifurtimox（Cat No.:R011691）is an antiparasitic medication used to treat Chagas disease, caused by Trypanosoma cruzi, and African trypanosomiasis (sleeping sickness). It works by producing reactive oxygen species within the parasite, leading to oxidative stress and damage to its DNA and cellular structures, ultimately causing parasite death. Nifurtimox is particularly effective in the acute phase of Chagas disease and is often used in combination with other treatments. Its ability to target the parasite’s metabolic processes makes it a vital tool in managing and controlling these neglected tropical diseases.
| Catalog Number | R011691 |
| CAS Number | 23256-30-6 |
| Synonyms | 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-Dioxide; 4-(5-Nitrofurfurylideneamino)-3-methylthiomorpholine 1,1-Dioxide; BAY 2502; Bayer 2502; Lampit; (+/-)-Nifurtimox; |
| Molecular Formula | C10H13N3O5S |
| Purity | 98% |
| Target Protein | P22513 |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | IC50s = 9.91, 12.28, and 10.44 μM against Taluahuén, LQ, and Brener strains of T |
| IUPAC Name | (E)-N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitrofuran-2-yl)methanimine |
| InChI | InChI=1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3/b11-6+ |
| InChIKey | ARFHIAQFJWUCFH-IZZDOVSWSA-N |
| SMILES | CC1CS(=O)(=O)CCN1/N=C/C2=CC=C(O2)[N+](=O)[O-] |
| Reference | 1:Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States. Forsyth CJ, Hernandez S, Olmedo W, Abuhamidah A, Traina MI, Sanchez DR, Soverow J, Meymandi SK.Clin Infect Dis. 2016 Oct 15;63(8):1056-1062. doi: 10.1093/cid/ciw477. Epub 2016 Jul 17. PMID: 27432838 Free PMC Article<br /> |
